Most recently she is the CFO of X4 Pharmaceuticals and is instrumental in building out the finance and legal infrastructure as well as crafting the story used for multiple financings.
Prior to this, she was the VP of Finance and Administration at Civitas Therapeutics, Inc where she was instrumental in establishing the infrastructure required for the planned public offering and the resulting sale to Acorda Therapeutics, Inc. Prior to that Ms. Franz served as the interim CFO of Kala Pharmaceuticals during the expansion of the management team and critical financings. Prior to that, Ms. Franz served as the CFO of BIND Biosciences (name changed to BIND Therapeutics) where she was instrumental in building out the financial infrastructure needed from early start-up research to a clinical state oncology company with multiple sources of funding (equity, government, partnerships, debt, public offering).
Other prior experience includes projects at Marathon Biopharmaceuticals (purchased by Lonza), Circe Biomedical (purchased by Arbios Systems), Millenium and others.
Andrea is a CPA and received her business degree from the University of New Hampshire.
